- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00858403
Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation
Phase II Study of Dasatinib in Advanced Non-small Cell Lung Cancer With Ex Vivo and In Vivo Assessment of Tumor Target Modulation
Studienübersicht
Detaillierte Beschreibung
Cycle 1 Day 1 (C1D1): Patients will have complete history and physical (H&P), complete blood count (CBC), complete metabolic panel (CMP) and electrocardiogram (EKG) on day 1. Each cycle is 28 days. The C1D1 EKG can be omitted if the patient has no new cardiac symptoms and has not starting taking any medication known to affect QT corrected for heart rate (QTc) prolongation. Any residual toxicity from prior therapy for cancer will be recorded. Blood will be drawn for assessment of serum markers. The patient will begin dasatinib at the starting C1D1 on a daily basis.
Cycle 1 Day 10-20 (C1D10-20): Patients will have a second biopsy to obtain additional tumor material to examine biological effects of dasatinib on signaling pathways. Dasatinib will be taken first thing in the morning and the patient will log the time. Blood will also be drawn for pharmacokinetic assessments of dasatinib levels in plasma and the time recorded. Four FNA aspirates and 2 core biopsies can be obtained either at the bedside for palpable lesions or through appropriate image-guided techniques (CT or US) at the discretion of the treating physician in consultation with radiology. The time of the biopsy will be recorded. One core biopsy should be immediately fixed in formalin and the other core biopsy should be snap frozen in liquid nitrogen.
Cycle 2 Day 1 (C2D1): Patients will be seen by the treating physician and have complete H&P, CBC, and CMP. Blood will be drawn for assessment of serum markers. Toxicity of dasatinib will be assessed. The patient will continue to take daily doses of dasatinib on a daily basis.
Cycle 2 Day 22 (C2D22): Patients will undergo reevaluation for tumor measurements. This assessment can occur on C2D22 ±7 days.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Florida
-
Tampa, Florida, Vereinigte Staaten, 33612
- H. Lee Moffitt Cancer Center & Research Institute
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Histologically or cytologically documented diagnosis of NSCLC that is advanced/metastatic (Stage IIIB/IV).
- Performance Status (ECOG) 0-2
- Previous chemotherapy with the exception of dasatinib. Patients who have had any type of previous chemotherapy regimens for non-small cell lung cancer are eligible.
Adequate Organ Function:
- Total bilirubin < 2.0 times the institutional Upper Limit of Normal (ULN)
- Hepatic enzymes (AST, ALT ) ≤ 2.5 times the institutional ULN
- Serum Na, K+, Mg2+, Phosphate and Ca2+≥ Lower Limit of Normal (LLN)
- Serum Creatinine < 1.5 time the institutional ULN
- Hemoglobin, Neutrophil count, Platelets, prothrombin time (PT), partial thromboplastin time (PTT) all Grade 0-1
- Ability to take oral medication
Concomitant Medications:
- Agree to discontinue St. Johns Wort while receiving dasatinib therapy
- Agree that IV bisphosphonates will be withheld for the first 8 weeks of dasatinib therapy due to risk of hypocalcemia.
Women of childbearing potential (WOCBP):
- A negative serum or urine pregnancy test within 72 hours prior to the start of study drug administration
- Persons of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped Prior to study enrollment.
- Signed written informed consent including a HIPAA form according to institutional Guidelines
Exclusion Criteria:
- No malignancy [other than the one treated in this study] which required radiotherapy or systemic treatment within the past 5 years.
- Prior dasatinib therapy.
Concurrent medical condition which may increase the risk of toxicity, including:
- Patients with severe pulmonary disease that increases the risk of toxicity related to dasatinib-induced pleural effusions. This includes chronic obstructive pulmonary disease or pleural effusions (malignant or benign) requiring chronic oxygen therapy or patients that have had prior pneumonectomy. Patients that have a pulmonary embolism and require oxygen therapy will be excluded but not those patients who have a pulmonary embolism but do not require oxygen therapy. Patients with active pleural effusions not controlled with pleurodesis will be excluded.
Cardiac Symptoms; any of the following should be considered for exclusion:
- Uncontrolled angina, congestive heart failure or MI within (6 months)
- Diagnosed congenital long QT syndrome
- Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
- Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)
- Patients with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration
History of significant bleeding disorder unrelated to cancer, including:
- Diagnosed congenital bleeding disorders
- Diagnosed acquired bleeding disorder within one year
- Ongoing or recent (≤ 3 months) significant gastrointestinal bleeding
Concomitant Medications, any of the following should be considered for exclusion:
Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (Patients must discontinue drug 7 days prior to starting dasatinib)
- quinidine, procainamide, disopyramide
- amiodarone, sotalol, ibutilide, dofetilide
- erythromycin, clarithromycin
- chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide
- cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine.
Women:
- unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after cessation of study drug,or
- have a positive pregnancy test at baseline
- pregnant or breastfeeding
- Prisoners or persons who are compulsorily detained (involuntarily incarcerated)for treatment of either a psychiatric or physical (e.g., infectious) illness
- Patients on systemic anticoagulation at risk of bleeding related to tumor biopsy that cannot be off anticoagulation per the discretion of their physician.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Treatment with Dasatinib
Dasatinib 140 mg orally (po) every day starting Day #1, continuous dosing.
This dose was chosen based on the current experience in patients with solids tumors who have had prior chemotherapy.
|
Take tablets of Dasatinib by mouth once a day.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Participant Progressors vs. Non-progressors With Tumor Response
Zeitfenster: 1 year, 4 months
|
We planned to assess whether the extent of inhibition of extracellular signal-regulated protein kinase (ERK) phosphorylation in lung cancer cells exposed ex vivo to dasatinib significantly differed between patients categorized as progressors or non-progressors through standard Response Evaluation Criteria In Solid Tumors (RECIST)
|
1 year, 4 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Participants With Response to Dasatinib
Zeitfenster: 1 year, 4 months
|
We planned to estimate the single agent response rate to dasatinib in this patient population
|
1 year, 4 months
|
Number of Participants With Progression Free Survival (PFS) at 6 Months
Zeitfenster: 1 year, 4 months
|
We planned to estimate the 6 month progression free survival rate of dasatinib in this patient population.
|
1 year, 4 months
|
Number of Participants With Serious Adverse Events (SAEs)
Zeitfenster: 1 year, 4 months
|
We evaluated toxicity of dasatinib in this patient population.
|
1 year, 4 months
|
Number of Participant Progressors vs. Non-Progressors With Inhibition Response
Zeitfenster: 1 year, 4 months
|
We planned to assess whether the extent of inhibition of proto-oncogene tyrosine-protein kinase (SRC) and protein kinase B (Akt) phosphorylation in lung cancer cells exposed ex vivo and in vivo to dasatinib significantly differs between patients categorized as progressors or non-progressors through standard RECIST criteria.
|
1 year, 4 months
|
Correlation Between Extent of Inhibition and Concentration of Dasatinib
Zeitfenster: 1 year, 4 months
|
We planned to explore whether the extent of inhibition of ERK, SRC and Akt phosphorylation in lung cancer cells exposed ex vivo to dasatinib will correlate with the drug concentration of dasatinib.
|
1 year, 4 months
|
Correlation Between Mutation and Inhibition and to Disease Control Rate and Response
Zeitfenster: 1 year, 4 months
|
To analyze Kras and epidermal growth factor receptor (EGFR) mutation and their correlation to the ERK pathway inhibition and to disease control rate and response.
|
1 year, 4 months
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Eric Haura, M.D., H. Lee Moffitt Cancer Center and Research Institute
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen der Atemwege
- Neubildungen
- Lungenkrankheit
- Neubildungen nach Standort
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Karzinom, bronchogen
- Bronchiale Neubildungen
- Lungentumoren
- Karzinom, nicht-kleinzellige Lunge
- Molekulare Mechanismen der pharmakologischen Wirkung
- Enzym-Inhibitoren
- Antineoplastische Mittel
- Proteinkinase-Inhibitoren
- Dasatinib
Andere Studien-ID-Nummern
- MCC-15656
- CA180214 (Andere Kennung: Bristol-Myers Squibb)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Lungenkrebs
-
Hal C CharlesAbgeschlossenKonstriktive Bronchiolitis | Irak-Afganistan War Lung Injury SyndromeVereinigte Staaten
-
Joseph MccuneEunice Kennedy Shriver National Institute of Child Health and Human Development... und andere MitarbeiterBeendetLupus erythematodes, systemisch | Systemische Vaskulitis | Lungenerkrankung mit systemischer Sklerose | Isolierte Angiitis des zentralen Nervensystems | Lung Disease Interstitial DiffusVereinigte Staaten
Klinische Studien zur Dasatinib
-
Bristol-Myers SquibbAbgeschlossenPharmakokinetische Studie an gesunden TeilnehmernVereinigte Staaten
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Abgeschlossen
-
Hyoung Jin KangNoch keine RekrutierungAkute lymphoblastische Leukämie, Pädiatrie
-
Xspray Pharma ABQPS Bioserve India Pvt LimitedAbgeschlossen
-
National Cancer Institute (NCI)ZurückgezogenNeoplasma hämatopoetischer und lymphoider Zellen | Fortgeschrittenes Lymphom | Fortgeschrittenes bösartiges solides Neoplasma | Refraktäres Lymphom | Refraktärer bösartiger fester Neoplasma | Refraktäres Plasmazell-MyelomVereinigte Staaten
-
National Cancer Institute (NCI)NRG OncologyBeendetRezidivierendes Eileiterkarzinom | Rezidivierendes Ovarialkarzinom | Rezidivierendes primäres Peritonealkarzinom | Klarzelliges Zystadenokarzinom der Eierstöcke | Klarzelliges Adenokarzinom des Endometriums | Wiederkehrender UteruskorpuskrebsVereinigte Staaten
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers SquibbAbgeschlossen
-
Norwegian University of Science and TechnologyAbgeschlossenLeukämie, myeloische, chronische PhaseSchweden, Finnland, Norwegen
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, nicht rekrutierendChronische myeloische Leukämie in der chronischen Phase, BCR-ABL1-positiv | Philadelphia-Chromosom-positiv, BCR-ABL1-positiv, chronische myeloische LeukämieVereinigte Staaten
-
Centro de Atencion e Investigacion MedicaNoch keine Rekrutierung